Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Dise
Go back to Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Dise| (NASDAQ: PVLA) | Delayed: 134.07 +4.23 (3.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $129.84 | 52 Week High | $ | |||
| Open | $130.80 | 52 Week Low | $ | |||
| Day High | $140.65 | P/E | N/A | |||
| Day Low | $130.80 | EPS | $ | |||
| Volume | 90,487 | |||||
